Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — Q1 2020 Earnings Presentation
16 slides from Myriad Genetics's earnings presentation, Nov 4, 2019
Slide 1: Myriad Genetics Fiscal First-Quarter 2020 Earnings Call
Myriad Genetics Fiscal First-Quarter 2020 Earnings Call November 4, 2019 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: Fiscal First-Quarter 2020 Financial Results
Fiscal First-Quarter 2020 Financial Results 1Q20 Actual Results 1Q19 Actual Results Revenue (in mil.) $186.3 $202.3 GAAP EPS ($0.28) ($0.01) Adjusted EPS $0.08 $0.43
Slide 4: Financial Overview
Financial Overview
Slide 5: Fiscal First-Quarter 2020 Revenue By Product
Fiscal First-Quarter 2020 Revenue By Product Product 1Q20 1Q19 YoY Growth Hereditary Cancer $104.5 $116.3 (10%) GeneSight® $22.7 $29.3 (22%) Prenatal Testing $23.5 $18.1 30% Vectra® $11.0 $13.0 (15%) Prolaris® $6.5 $6.2 5% EndoPredict® $2.3 $2.4 (4%) Other $1.5 $3.7 (60%) Total Molecular Diagnostic
Slide 6: Fiscal First-Quarter 2020 Financial Results
Fiscal First-Quarter 2020 Financial Results GAAP Results Adjusted Results 1Q20 1Q19 YoY Growth 1Q20 1Q19 YoY Growth Total Revenue $186.3 $202.3 (8%) $186.3 $202.3 (8%) Gross Profit $136.6 $152.6 (10%) $137.1 $155.9 (12%) Gross Margin 73.3% 75.4% -210 bps 73.6% 77.1% -350 bps Operating Income ($20.9)
Slide 7: FY20 and 2Q FY20 Financial Guidance
FY20 and 2Q FY20 Financial Guidance Metric Fiscal Year 2020 2Q FY20 Revenue $800-$810 million $210-$212 million GAAP Diluted EPS ($0.25)-($0.15) ($0.02)-$0.00 Adjusted EPS $1.00-$1.10 $0.30-$0.32
Slide 8: Publication of the Precision Medicine Analysis from GUIDED Outcomes at Week-8
Publication of the Precision Medicine Analysis from GUIDED Outcomes at Week-8 1 Thase et al: Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized, controlled trial
Slide 9: New Medicare Draft LCDs for GeneSight from MolDx
New Medicare Draft LCDs for GeneSight from MolDx Broad Pharmacogenomic LCD Combinatorial LCD LCD LCD Covers primary care physicians Covers anxiety Similar to UnitedHealthcare Medical Policy Ordered by a psychiatrist for major depressive disorder Combinatorial LCD: https://www.cms.gov/medicare-covera
Slide 10: Opportunities for BRACAnalysis CDx With PARP Inhibitors
Opportunities for BRACAnalysis CDx With PARP Inhibitors Cancer Type Incident Population* Launch Timing Pancreatic Cancer (POLO study) 57,000 1H FY20 Castrate Resistant Metastatic Prostate Cancer (PROfound) 32,000 2H FY20 Adjuvant HER2- Breast Cancer (OlympiA Study) 198,000 FY21 * cancer.net, https:/
Slide 11: myChoice CDx FDA Approved – October 23rd
myChoice CDx FDA Approved – October 23rd
Slide 12: Opportunities with myChoice CDx
Opportunities with myChoice CDx Indication/Drug Incident Population* Launch Timing Ovarian Cancer U.S. 15,000 patients Approved Ovarian Cancer Japan 9,000 patients FY21 1st Line Ovarian Cancer (olaparib, niraparib, veliparib) U.S & Europe 50,000 patients Seeking clarity from regulators and commercia
Slide 13: Prequel is the Most Accurate NIPS Test in Women With High BMI
Prequel® is the Most Accurate NIPS Test in Women With High BMI Source: Muzzey et al: Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk No call rate of up to 24% in high BMI wo
Slide 14: Vectra Additive to All Other Cardiovascular Risk Predictive Measures
Vectra Additive to All Other Cardiovascular Risk Predictive Measures 1 Source – ACR Abstract: Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis Highly validated in 30,751 patients 28% of patients determined to be high risk by American Heart A
Slide 15: New Prolaris Clinical Utility Data
New Prolaris Clinical Utility Data % of Patients Remaining on Active Surveillance 82% of patients selected active surveillance as initial therapy Only 0.4% of patients selecting active surveillance experienced disease progression Source: Kaul et al: Clinical outcomes in men with prostate cancer who
Slide 16: Potential Upside Drivers to Financial Guidance
Potential Upside Drivers to Financial Guidance Product Catalysts NCCN breast cancer guidelines Regional payer collections progress U.S. CDx for pancreatic cancer Japan CDx for ovarian cancer U.S. CDx for prostate cancer Japan hereditary cancer Commercial payer coverage Large PBM master service agree